Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2026. The report discloses the granting of awards under the Deferred Investment Award Programme to Persons Discharging Managerial Responsibilities (PDMRs) on February 12, 2026. These awards are notional Ordinary Shares intended to align long-term interests with shareholders and reward outstanding performance during 2025.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific equity compensation transactions:
- Instrument: Notional Ordinary Shares (31 1/2 pence each, ISIN: GB00BN7SWP63).
- Transaction Price: £21.41 per share.
- Volume per Recipient: 3,020 shares.
- Total Notional Value per Recipient: £64,658.20 (calculated as 3,020 shares × £21.41).
Material Changes
The filing reports the initial notification of restricted awards granted to two newly appointed Executive Committee members. There are no reported material changes to the company's financial position, operations, or capital structure beyond these specific compensation grants.
Guidance, Outlook, and Risks
Management Commentary: The awards were granted to Lynn Baxter (President, Europe) and Mondher Mahjoubi (Chief Patient Officer) as part of the general employee performance system. Executive Directors are explicitly excluded from this specific programme.
Terms and Conditions:
- Vesting Period: Awards vest on February 12, 2029 (3-year term).
- Settlement: Awards are paid in cash upon vesting; no dividends accrue during the vesting period.
- Conditions: Vesting is contingent on the PDMR not having served notice of resignation or been terminated for cause.
Risks and Contingencies: The filing does not disclose new material risks or legal contingencies. The primary contingency is the employment status of the recipients through the vesting date.
Investor Verification Checklist
- Verify the total number of PDMRs receiving awards under this programme to assess aggregate compensation impact.
- Confirm the share price of £21.41 against the market price on February 12, 2026, to determine if the grant was at fair market value.
- Review the company's annual report (Form 20-F) for the full scope of the Deferred Investment Award Programme and its impact on equity-based compensation expenses.
- Monitor future filings for the vesting status of these awards in 2029.